The New Hardware Race: How AI, Electric Vehicles, and Biotech Are Converging in 2025

The Lines Are Blurring Between Digital and Physical

If you still think of AI, electric vehicles, and biotech as separate industries, 2025 is the year to update that mental model. The most consequential product launches and business moves this year sit right at the intersection of these domains. Foundation models are being fine-tuned for autonomous driving stacks. Large language models are parsing clinical trial data to accelerate drug discovery. Electric vehicle platforms are being designed around silicon-first architectures where software updates change the car’s character more than mechanical revisions ever did.

This isn’t science fiction — it’s happening now, and it’s reshaping capital allocation, talent markets, and competitive strategy across every major technology sector. In this post, we’ll walk through what’s actually moving the needle in AI, EVs, and biotech, and why the convergence of these fields is creating opportunities (and risks) that were barely on the radar two years ago.

The AI Model Landscape: Multimodal Becomes Mainstream

From Text to Everything

The AI story in 2025 is no longer just about chat. Multimodal models — systems that can natively understand and generate text, images, audio, and structured data — have become the default expectation. OpenAI’s GPT-4o, Google’s Gemini 1.5 Pro, and Anthropic’s Claude 3.5 Sonnet all treat images, voice, and code as first-class citizens in the same context window. That shift matters because it means the interface to AI is moving toward natural, multimodal conversation rather than typed prompts in a text box.

What’s notable is that open-source alternatives have closed much of the gap. Meta’s Llama 3.1 series, Mistral’s Mixtral 8x22B, and France-based Mistral AI’s latest offerings provide surprisingly capable multimodal reasoning at a fraction of the closed-source cost. For enterprises, this has meant a real reckoning: do you pay a premium for proprietary frontier models, or invest in fine-tuning open models on your own data? The answer increasingly depends on your latency tolerance and regulatory constraints, not raw capability.

The Small Model Revolution

Equally important is the rise of small, efficient models that run on-device. Apple’s on-device AI initiative, Qualcomm’s NPU-focused optimizations, and Microsoft’s Phi-3 family have made it clear that not every AI task requires a datacenter. Running inference locally solves privacy concerns, reduces latency to near-zero, and cuts cloud costs dramatically. For consumer-facing applications like real-time translation, on-device transcription, and personal assistants, edge AI is rapidly becoming the default.

This shift has also changed the economics of AI startups. The companies that win in 2025 aren’t necessarily the ones with the biggest models — they’re the ones with the most efficient deployment strategy, the best tooling for fine-tuning, and the sharpest focus on specific use cases rather than general-purpose chatbot wrappers.

Cars Become Computers on Wheels

The Software-Defined Vehicle

The automotive industry’s transformation into a software-first business is no longer a hypothesis — it’s the core competitive battleground. Tesla’s Full Self-Driving version 12, built entirely on neural networks with minimal hard-coded rules, marked a significant milestone. The industry is now watching closely as Tesla rolls out supervised autonomy features and as competitors like BYD, Xpeng, and Mercedes-Benz deploy their own vision-based and lidar-assisted stacks.

But the bigger story isn’t just autonomy — it’s the entire vehicle becoming a software platform. Ford, GM, Hyundai, and virtually every major automaker have committed to over-the-air update architectures. These aren’t the limited connectivity updates of a decade ago. Modern EVs can receive performance tuning maps, battery management improvements, infotainment feature drops, and even suspension tuning via software. The car you buy today will be substantively different — and hopefully better — in a year thanks to code, not mechanical modifications.

EV Economics and the Battery Plateau

Electric vehicle sales continue to grow globally, but the narrative has shifted from "EVs are the future" to "which EVs can survive the margin squeeze." Battery prices, which fell dramatically from 2018 through 2023, have plateaued due to raw material costs and supply chain constraints. Automakers are responding by focusing on platform sharing, second-life battery applications, and vertical integration into mining and refining.

The Chinese EV market is leading the charge in affordability, with models from BYD and Leapmotor undercutting Western competitors on price while closing quality gaps. In Europe, the EU’s 2035 ICE ban is driving accelerated adoption, though infrastructure bottlenecks remain acute. In the US, policy uncertainty has slowed investments, but consumer demand for affordable EVs hasn’t collapsed — it’s waiting for the right product at the right price point.

Biotech Hits an Inflection Point

The GLP-1 Ripple Effect

The most recognizable biotech story in recent memory is the GLP-1 agonist revolution. Semaglutide and tirzepatide have proven that obesity and metabolic disease can be treated with pharmaceutical intervention at scale. The impact extends far beyond weight loss — these drugs are showing promise in treating cardiovascular disease, sleep apnea, osteoarthritis, and potentially even cognitive decline. The market is reacting accordingly: Eli Lilly and Novo Nordisk have become two of the most valuable healthcare companies in the world, and dozens of competitors are racing to develop next-generation GLP-1 molecules with improved delivery profiles and oral formulations.

AI-Driven Drug Discovery

Beneath the GLP-1 headlines, a quieter revolution is reshaping how drugs are discovered. Companies like Recursion Pharmaceuticals, Insilico Medicine, and Isomorphic Labs (DeepMind’s spin-off) are using deep learning to screen molecular libraries, predict protein structures, and generate novel candidate compounds. The pitch is simple: compress the typical 10-to-15-year drug discovery timeline to 2-to-3 years and reduce failure rates in late-stage trials.

Progress is tangible. Recursion’s partnership with Roche on fibrotic diseases, Insilico’s AI-discovered treatment for idiopathic pulmonary fibrosis that reached Phase II trials, and Google DeepMind’s AlphaFold ecosystem for structural biology all point toward an industry where AI is a core research tool rather than a supplementary technology. The next milestone will be an AI-discovered drug reaching Phase III and ultimately approval — when that happens, the industry’s skepticism about AI-driven drug discovery will likely evaporate.

Gene Therapy Goes Mainstream

CRISPR-based gene editing continues to mature from laboratory curiosity to clinical reality. The FDA’s approval of treatments for sickle cell disease and transfusion-dependent beta-thalassemia have set regulatory precedents that other gene therapy developers are following. The challenge now is manufacturing: getting these therapies from clinical trial batches to scalable commercial production while maintaining the safety profile that gene editing demands.

Base editing and prime editing — more precise derivatives of CRISPR — are advancing through preclinical and early clinical stages. These technologies promise to correct genetic mutations without the double-strand breaks associated with classic CRISPR-Cas9, potentially reducing off-target effects significantly. The next two to three years will be decisive in determining whether base editing can deliver on that promise at scale.

Where These Worlds Collide

The most interesting narratives in 2025 aren’t confined to single sectors — they emerge from the intersections. AI-powered drug discovery relies on the same underlying transformer architectures that power customer service chatbots. Autonomous driving systems depend on sensor fusion and neural network inference techniques that originated in natural language processing. Electric vehicle platforms require battery chemistry advances that are being accelerated by computational materials science — which is itself an AI application.

For investors, engineers, and entrepreneurs, the implication is clear: domain expertise in one area is still valuable, but the ability to learn the language and tools of adjacent fields is becoming the defining competitive advantage. The companies and individuals that can operate at these intersections will be better positioned to identify opportunities, allocate resources, and build products that don’t just improve on existing paradigms but redefine them entirely.

Looking Ahead

We’re in the early innings of a multi-decade reconfiguration of technology industries. AI is becoming infrastructure, EVs are becoming computers on wheels, and biotech is becoming a data science discipline. Each of these transitions creates dislocation for incumbents and opportunity for newcomers. The winners won’t necessarily be the biggest or the most well-funded — they’ll be the ones with the clearest understanding of how these shifts connect and how to build products that embrace the convergence rather than fighting it.

For those watching these markets, the key takeaway is this: focus less on whether AI is overhyped, or whether EVs will dominate by 2030, or whether gene editing will live up to its promise. The more productive question is which organizations — and which people — are best positioned to operate across these domains simultaneously. That’s where the next decade of technology value will be created.